Related Experiment Video

Updated: Jul 15, 2025

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.2K

Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?

Tarek Assi1, Axel Le Cesne1

  • 1Division of International Patients Care, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805, Villejuif, France.

Future Oncology (London, England)
|October 2, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Sarcomachemotherapyradiotherapysoft tissuetrabectedin

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

Related Experiment Videos

Last Updated: Jul 15, 2025

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

HMGA2::NCOR2 fusion-driven giant cell tumors: Diagnosis and treatment.

Critical reviews in oncology/hematology·2026

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Cancer·2026

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.

Current treatment options in oncology·2026

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026

Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma.

Future oncology (London, England)·2026

Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.

Future oncology (London, England)·2026

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.

Future oncology (London, England)·2026

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.

Future oncology (London, England)·2026

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Future oncology (London, England)·2026

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

[Evaluation of tolerability and cognitive safety of trospium chloride in the treatment of overactive bladder: a systematic review and meta-analysis].

Urologiia (Moscow, Russia : 1999)·2026

[Innovative approaches to carboxyperitoneum creation: experimental developments and clinical perspectives].

Urologiia (Moscow, Russia : 1999)·2026

[Risk factors of postoperative urinary retention in patients with intradural extramedullary spinal cord tumors].

Urologiia (Moscow, Russia : 1999)·2026

[Complex therapy of chronic bacterial prostatitis using the immunomodulatory drug sodium aminodihydrophthalazinedione].

Urologiia (Moscow, Russia : 1999)·2026

Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023).

The oncologist·2026

Bronchial stump re-resection for carcinoid tumor recurrence after left pneumonectomy: Case report.

Turk gogus kalp damar cerrahisi dergisi·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us